Marlise Rachael Luskin, M.D.
This page shows the publications co-authored by Marlise Luskin and Donna Neuberg.
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. Am J Hematol. 2021 07 01; 96(7):E259-E262.
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 Mar 15; 1-8.
Prediction of Life-threatening and Disabling Bleeding in Patients with AML Receiving Intensive Induction Chemotherapy. Blood Adv. 2022 Jan 26.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.